NCT03424941已完成不适用
TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention Versus Conventional Surgical Aortic Valve Replacement and Coronary By-Pass Grafts for Treatment of Patients with Coronary MultiVessel Disease and Aortic Valve Stenosis
Maatschap Cardiologie Zwolle21 个研究点 分布在 10 个国家目标入组 172 人开始时间: 2018年5月31日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 发起方
- 入组人数
- 172
- 试验地点
- 21
- 主要终点
- The primary endpoint is a composite of all-cause mortality, myocardial infarction, disabling stroke, unscheduled clinically-driven target vessel revascularization, valve re-intervention, and life threatening or disabling bleeding at one year
研究概览
简要总结
The trial objective is to investigate whether Fractional Flow Reserve (FFR)-Guided Percutaneous Coronary Intervention (PCI) and TransCatheter Aortic Valve Implantation (TAVI) strategy for treatment of multivessel disease and aortic stenosis will be non-inferior to Coronary Artery By-pass Grafting (CABG) and Surgical Aortic Valve Replacement (SAVR) for a composite primary endpoint of all-cause mortality, stroke, myocardial infarction, coronary or valve re-intervention and life-threatening or disabling bleeding at one year.
详细描述
Prospective, randomized, controlled, open label, multicenter, international, non-inferiority trial
If the Heart Team decides that a coronary revascularization and aortic valve replacement is needed and the patient complies with inclusion and exclusion criteria then the patient will be randomized in a 1:1 fashion between FFR-guided PCI + TAVI and CABG + SAVR.
Patients will receive optimal medical treatment at discharge. Follow-up will be performed at 30 days and at one year. During the 30 day follow-up visit (after TAVI) patients will be evaluated for symptoms of angina.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 70 Years 至 —（Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Symptomatic patients aged ≥70 years with aortic stenosis fulfilling one of these criteria (Aortic Valve Area (AVA) ≤1 cm2; mean gradient ≥40 mmHg; Aortic jet velocity >4 m/sec; or Velocity index ≤ 0.25) feasible for treatment by both trans femoral or subclavian approach TAVI as well as conventional SAVR and where the Heart Team decides that treatment is needed (final decision is left to the Heart Team)
- •Presence of ≥2 de novo coronary lesions of ≥50% diameter stenosis on visual estimation located in any of main epicardial coronary arteries, or side branches of a lumen caliber of more than 2 mm or single Left Anterior Descending (LAD) lesion with more than 20 mm length or involving a bifurcation (complex), feasible for treatment with CABG as well as PCI (Heart Team decision)
- •Patients willing and capable to provide written informed consent
排除标准
- •Patients in cardiogenic shock or acute heart failure, requiring inotropic agents during procedure and/or i.v. diuretics <48 hours before procedure
- •Left ventricular ejection fraction <30%
- •Concomitant presence of other than aortic valve disease requiring intervention
- •Previous CABG, SAVR, TAVI or thoracotomy for any other reason
- •Bicuspid or unicuspid aortic valve
- •Recent myocardial infarction (less than 2 weeks)
- •Involvement of left main trifurcation (all three branches being larger than 2 mm)
- •Expected total stent length more 60mm per vessel
- •FFR measurement judged impossible
- •Life expectancy <1 year
- •Known malignancy
- •Contraindication for dual antiplatelet therapy or expected surgical intervention requiring interruption of Dual Antiplatelet Therapy (DAPT) in the first 6 months
- •Reduced renal function (Glomerular Filtration Rate (GFR) <29 ml/min/1.73m2; Kidney Disease Outcomes Quality Initiative (KDOQI) stage 4 and 5)
- •Previous disabling stroke, Transient Ischemic Attack (TIA) in the last 6 months, or known severe stenosis of carotid or vertebral arteries
- •Participation in other investigational clinical trials
结局指标
主要结局
The primary endpoint is a composite of all-cause mortality, myocardial infarction, disabling stroke, unscheduled clinically-driven target vessel revascularization, valve re-intervention, and life threatening or disabling bleeding at one year
时间窗: one year
次要结局
- All-cause mortality and all stroke at 30 days and at one year(30 days and one year)
- Device success (Valve Academic Research Consortium (VARC) 2 definition)(procedure)
- Quality of life (Short Form (SF)-36) before treatment and at one year(one year)
- Life-threatening or disabling bleeding at 30 days and one year(30 days and one year)
- Access-related complications at 30 days(30 days)
- Early Safety at 30 days (VARC 2 definition)(30 days)
- Echocardiographic assessment of prosthetic valve performance at discharge and at one year using the following measures: a) transvalvular mean gradient, b) Effective Orifice Area (EOA), c) degree of prosthetic aortic valve regurgitation(discharge and at one year)
- Change in New York Heart Association (NYHA) class before treatment, at 30 days and at one year(30 days and one year)
- Major Adverse Cardiac Events (MACE: a composite of cardiovascular mortality, all stroke, myocardial infarction, unscheduled coronary or valve re-intervention) at one year(one year)
- Acute kidney injury (Acute Kidney Injury Network (AKIN) classification) at 30 days and at one year(30 days and one year)
- Stent thrombosis according to Academic Research Consortium (ARC) criteria (definite and probable) at 30 days and at one year(30 days and one year)
- Time Related Valve Safety at 30 days (VARC 2 definition)(30 days)
- Clinically driven revascularisation at 30 days and at one year(30 days and one year)
- Rate of conduction disturbances requiring a permanent pacemaker at 30 days and at one year(30 days and one year)
- Life-threatening or disabling bleeding and major bleeding at 30 days and at one year(30 days and one year)
- Early Efficacy at 30 days (VARC 2 definition)(30 days)
- Change in Canadian Cardiovascular Society (CCS) class before treatment, at 30 days and at one year(30 days and one year)
研究者
研究点 (21)
Loading locations...
相似试验
已完成
4 期
Optical Coherence Tomography to Investigate FFR-Guided DEB-only Elective Coronary AngioplastyCoronary StenosisStable AnginaNCT02120859University of Jena50
招募中
不适用
TransCatheter Aortic Valve Implantation and Fractional Flow Reserve-Guided Percutaneous Coronary Intervention versus Conventional Surgical Aortic Valve Replacement and Coronary By-Pass Grafts for Treatment of Patients with Coronary MultiVessel Disease and Aortic Valve Stenosismeervatslijdenmultivessel disease and aortic valve stenosis10046973NL-OMON50705Maatschap Cardiologie Zwolle170
终止
不适用
Effect of FFR Guided Percutaneous Coronary Intervention in Coronary Tandem LesionsPercutaneous Transluminal Coronary AngioplastyNCT02797561Seung-Jung Park438
已完成
不适用
Role of On-site CT-derived FFR in the Management of Suspect CAD PatientsCoronary Artery DiseaseNCT03901326Chinese PLA General Hospital1,216
进行中（未招募）
不适用
FFR Versus IVUS With Angiography-Derived FFR for Clinical Outcomes in Patients With Coronary Artery DiseaseCoronary Artery DiseaseNCT06218485Second Affiliated Hospital, Zhejiang University, School of Medicine1,942